Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO

Watchlist Manager
Crescent Biopharma Inc (Pre-Reincorporation) Logo
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Watchlist
Price: 14.4 USD 4.35% Market Closed
Market Cap: 200m USD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of CBIO.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CBIO Intrinsic Value
Not Available
Base Case Scenario
Compare CBIO to

Fundamental Analysis

Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
US
Biotechnology
Market Cap
200m USD
IPO
Jan 10, 2014
US
Biotechnology
Market Cap
200m USD
IPO
Jan 10, 2014
Price
$false
EPS
$false
Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CBIO?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Crescent Biopharma Inc (Pre-Reincorporation)
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Crescent Biopharma Inc (Pre-Reincorporation)

Current Assets 11.1m
Cash & Short-Term Investments 10.7m
Receivables 136.6k
Other Current Assets 234.7k
Efficiency

Free Cash Flow Analysis
Crescent Biopharma Inc (Pre-Reincorporation)

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Crescent Biopharma Inc (Pre-Reincorporation)

Revenue
0 USD
Operating Expenses
-32.5m USD
Operating Income
-32.5m USD
Other Expenses
-5.4m USD
Net Income
-37.9m USD
Fundamental Scores

CBIO Profitability Score
Profitability Due Diligence

Crescent Biopharma Inc (Pre-Reincorporation)'s profitability score is 18/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Negative 3Y Average Net Margin
Negative 3Y Average Operating Margin
Declining ROE
18/100
Profitability
Score

Crescent Biopharma Inc (Pre-Reincorporation)'s profitability score is 18/100. The higher the profitability score, the more profitable the company is.

CBIO Solvency Score
Solvency Due Diligence

Crescent Biopharma Inc (Pre-Reincorporation)'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
53/100
Solvency
Score

Crescent Biopharma Inc (Pre-Reincorporation)'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CBIO Price Targets Summary
Crescent Biopharma Inc (Pre-Reincorporation)

Wall Street analysts forecast CBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CBIO is 26.01 USD with a low forecast of 22.22 USD and a high forecast of 29.4 USD.

Lowest
Price Target
22.22 USD
54% Upside
Average
Price Target
26.01 USD
81% Upside
Highest
Price Target
29.4 USD
104% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for CBIO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CBIO Insider Trading
Buy and sell transactions by insiders

CBIO News